|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Strong cytoplasmic staining for CCR7 correlated with the presence of epithelioid cells (P = 0.037), tumor thickness (P = 0.011), lymphocytic infiltration (P = 0.041), and necrosis (P = 0.045).
|
24052640 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CCR7(+) tumor cells and FOXP3(+) Tregs were assessed by immunohistochemistry in tissue microarrays containing gastric cancer from 133 patients.
|
24040244 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The anti-CCR7 therapy significantly delayed the tumor appearance and also reduced the volumes of tumors in the subcutaneous model.
|
24305507 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR-engineered CCR7(-) T cells more efficiently accumulated at the tumor site, secreted more IFN-γ, expressed higher amounts of cytotoxic molecules, and showed superior tumor cell lysis compared to the younger CCR7(+) cells.
|
23350854 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that EVI1 is a critical player in tumor growth in a subset of MLL-rearranged AMLs.
|
22553314 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among these genes, increased expression of CCR7 in CD44+ CSCs was confirmed in NPC xenografts and primary tumors.
|
23285037 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
It also indicates that although the t(3;3)/EVI1 rearrangement is mostly related to myelocytic neoplasms, the t(3;3)/EVI1-rearrangement may also play an important role in the development of ALL.
|
23054648 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The Cox regression analysis showed tumor T classification, positive expression of CCR7/VEGF-C mRNA, and positive expression of CCR7/VEGF-C protein in tumor tissues to be independent risk factors for 3 year recurrence.
|
22644515 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of chemokine receptors CCR7 has been studied in relation to tumor dissemination and poor prognosis in a limited number of cancers.
|
21548969 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings open the way to further studies aimed at identifying the culprit EVI1 implicated tumour suppressor genes on 7q.
|
20084277 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ccr7 gene expression is controlled by the activity of the T-ALL oncogene Notch1 and is expressed in human tumours carrying Notch1-activating mutations.
|
19536265 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our data support the notion that CCR3, CCR7, and CXCR4 are increasingly expressed in tumor cells from PTC and that CXCR4 expression in PTC could be a potential marker for enhanced tumor aggressiveness.
|
19731977 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High-intensity IHC staining for CXCR4 was associated with larger tumor size (P = .02), while PTCs exhibiting ETE, ALI, or lymph node metastasis showed higher-intensity IHC staining for CCR7 than those without (P = .01, .03, and .01, respectively).
|
18696160 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The RUNX1/EVI1 chimeric transcription factor produced by t(3;21) causes leukemic transformation in hematopoietic stem cell tumors, possibly through a differentiation block of malignant myeloid progenitors.
|
17894555 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In diverse tumor entities, expression of the chemokine receptor, CCR7, has been linked to tumor dissemination and poor prognosis.
|
16786131 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The EVI1 gene locus was amplified in 43% of the tumors, and there was a significant correlation (P = 0.029) between gene copy number and EVI1 gene expression.
|
16951150 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, the prognosis of patients with CCR7-positive tumors was better than that of patients with CCR7-negative tumors, but no such correlation was observed for CXCR4 expression.
|
15867478 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monoclonal antibodies to CCR7 showed intense staining in the patient's tumor epithelium.
|
16018941 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CCR7 chemokine-receptor expression on tumour cells of gastric carcinoma has been associated with lymph-node metastasis and is thought to play an important role in metastasis.
|
15654831 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The ectopic expression of EVI1 (3q26) has been implicated in the dysplasia that characterizes this subset of myeloid neoplasias.
|
15138998 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Freshly sorted metastatic cells and tumour cell lines derived from the liver of BALB/c mice overexpressed functional CCR6 and CCR7 molecules compared with primary tumour.
|
12791091 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients with CCR7-positive tumors had a significantly poorer prognosis than those with CCR7-negative tumors (P < 0.05).
|
12019175 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicate that specific HDAc inhibitors may be useful in the treatment of Evi-1-induced neoplastic tumors, including myeloid leukemias.
|
11587364 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the aspect of potential therapeutic approaches, some pharmaceutical drugs or antisense oligonucleotides that repress Evi-1 expression would be useful for the treatment of Evi-1-induced neoplastic tumors.
|
10641791 |
1999 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The blast crisis of CML has been variably associated with abnormalities of proto-oncogenes, such as RAS and MYC, or of tumour suppressor genes, in particular RB, p53 and p16, or with the generation of chimeric transcription factors, as in the AML1-EVI1 gene fusion.
|
8656667 |
1996 |